Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.11

Margin Of Safety %

10

Put/Call OI Ratio

0.6

EPS Next Q Diff

-0.94

EPS Last/This Y

1.32

EPS This/Next Y

-0.19

Price

98.93

Target Price

106.29

Analyst Recom

2.04

Performance Q

16.92

Relative Volume

0.98

Beta

0.31

Ticker: MRK




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10MRK86.740.660.58678250
2025-11-11MRK90.950.660.19681243
2025-11-12MRK91.490.610.20723181
2025-11-13MRK930.600.18750328
2025-11-14MRK92.960.620.20747668
2025-11-17MRK92.880.630.48722881
2025-11-18MRK96.610.630.31729829
2025-11-19MRK95.090.620.66743983
2025-11-20MRK94.970.631.33752759
2025-11-21MRK97.790.620.24754676
2025-11-24MRK100.410.610.15666468
2025-11-25MRK105.650.540.65745673
2025-11-26MRK104.680.560.43763610
2025-12-01MRK101.850.581.14724877
2025-12-02MRK101.060.590.78739755
2025-12-03MRK102.320.600.57748445
2025-12-04MRK100.890.610.75754082
2025-12-05MRK99.720.610.55760107
2025-12-08MRK98.960.600.06742619
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10MRK86.7518.45660.68.96
2025-11-11MRK90.9518.46770.68.96
2025-11-12MRK91.4619.25665.68.97
2025-11-13MRK92.9419.25219.38.97
2025-11-14MRK92.9519.14812.58.97
2025-11-17MRK92.8419.14785.08.97
2025-11-18MRK96.4619.15791.18.97
2025-11-19MRK95.0519.14444.28.97
2025-11-20MRK94.9619.14782.88.96
2025-11-21MRK97.7619.25553.38.97
2025-11-24MRK100.4119.25725.88.97
2025-11-25MRK105.6619.36378.08.97
2025-11-26MRK104.6419.34781.78.97
2025-12-01MRK101.8418.94293.58.97
2025-12-02MRK101.0318.94827.78.97
2025-12-03MRK102.2718.95346.28.97
2025-12-04MRK100.8918.94683.48.97
2025-12-05MRK99.7218.94731.48.97
2025-12-08MRK98.9318.9- 8.97
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10MRK-0.31-0.701.08
2025-11-11MRK-0.31-0.701.08
2025-11-12MRK-0.57-0.701.04
2025-11-13MRK-0.57-0.701.04
2025-11-14MRK-0.57-0.701.04
2025-11-17MRK-0.570.101.04
2025-11-18MRK-0.570.101.04
2025-11-19MRK-0.570.101.04
2025-11-20MRK-0.570.101.04
2025-11-21MRK-0.570.101.04
2025-11-24MRK-0.52-1.211.04
2025-11-25MRK-0.63-1.211.04
2025-11-26MRK-0.63-1.211.11
2025-12-01MRK-0.63-1.291.11
2025-12-02MRK-0.63-1.291.11
2025-12-03MRK-0.63-1.291.11
2025-12-04MRK-0.63-1.291.11
2025-12-05MRK-0.63-1.291.11
2025-12-08MRK-0.63-1.221.11
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

2.58

Avg. EPS Est. Current Quarter

2.05

Avg. EPS Est. Next Quarter

1.64

Insider Transactions

-0.63

Institutional Transactions

-1.22

Beta

0.31

Average Sales Estimate Current Quarter

16183

Average Sales Estimate Next Quarter

16020

Fair Value

108.83

Quality Score

97

Growth Score

77

Sentiment Score

31

Actual DrawDown %

26.5

Max Drawdown 5-Year %

-43.4

Target Price

106.29

P/E

13.09

Forward P/E

11.22

PEG

1.29

P/S

3.84

P/B

4.75

P/Free Cash Flow

18.82

EPS

7.56

Average EPS Est. Cur. Y​

8.97

EPS Next Y. (Est.)

8.78

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

29.79

Relative Volume

0.98

Return on Equity vs Sector %

9.8

Return on Equity vs Industry %

0.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Merck & Company, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading